The article reviews the role of Monocyte Chemoattractant Protein-1 (MCP-1, also known as CCL2) as an inflammatory biomarker in various types of nephropathy. MCP-1, a chemokine, plays a crucial role in innate immunity and tissue inflammation, particularly in kidney diseases. It induces the migration and activation of immune cells, promotes monocyte and macrophage infiltration, and contributes to renal fibrosis. MCP-1 has been extensively studied in primary nephropathy, including crescentic glomerulonephritis, chronic glomerulonephritis, primary glomerulopathy, idiopathic proteinuria glomerulopathy, and acute kidney injury. In secondary nephropathy, such as diabetic nephropathy and lupus nephritis, MCP-1 is associated with disease severity and prognosis. In hereditary nephropathy, MCP-1 is linked to autosomal dominant polycystic kidney disease and sickle cell kidney disease, influencing cyst growth and renal function. The article highlights the potential of MCP-1 as a non-invasive biomarker for early detection and monitoring of kidney disease progression, emphasizing its utility in clinical settings. However, the specificity and sensitivity of MCP-1 as a biomarker are noted to be relatively low, suggesting the need for further research to improve its diagnostic value.The article reviews the role of Monocyte Chemoattractant Protein-1 (MCP-1, also known as CCL2) as an inflammatory biomarker in various types of nephropathy. MCP-1, a chemokine, plays a crucial role in innate immunity and tissue inflammation, particularly in kidney diseases. It induces the migration and activation of immune cells, promotes monocyte and macrophage infiltration, and contributes to renal fibrosis. MCP-1 has been extensively studied in primary nephropathy, including crescentic glomerulonephritis, chronic glomerulonephritis, primary glomerulopathy, idiopathic proteinuria glomerulopathy, and acute kidney injury. In secondary nephropathy, such as diabetic nephropathy and lupus nephritis, MCP-1 is associated with disease severity and prognosis. In hereditary nephropathy, MCP-1 is linked to autosomal dominant polycystic kidney disease and sickle cell kidney disease, influencing cyst growth and renal function. The article highlights the potential of MCP-1 as a non-invasive biomarker for early detection and monitoring of kidney disease progression, emphasizing its utility in clinical settings. However, the specificity and sensitivity of MCP-1 as a biomarker are noted to be relatively low, suggesting the need for further research to improve its diagnostic value.